Nanjing
China
Nanjing Vazyme Biotech Co., Ltd.
Heterologous boost, aerosolized adenovirus type-5 vector-based COVID-19 vaccine, safety, immunogenicity, inactivated COVID-19 vaccine, clinical trial
SARS-CoV-2, heterologous immunisation, recombinant adenovirus type-5-vectored COVID-19 vaccine, protein-subunit-based COVID-19 vaccine, clinical trial